Results of three consecutive completed UK trials (1980)(1981)(1982)(1983)(1984)(1985)(1986)(1987)(1988)(1989)(1990)(1991)(1992)(1993)(1994)(1995)(1996)(1997) for childhood lymphoblastic leukaemia are presented. National accrual has progressively increased so that over 90% of all the country's ALL cases were treated on the latest trial reported, UKALLXI. From 1980 to 1990, event-free and overall survival progressively improved, following adoption of an American therapy template and use of two post-remission intensification modules. Since 1990 despite demonstration of the benefit of a third intensification module overall event-free survival (EFS) has not improved further. Survival remains high due to a good retrieval rate especially for those relapsing off treatment after receipt of two intensification pulses. Possible reasons for the plateau in event-free survival (including type and dose of induction steroid, dropping of induction anthracycline, type and dose of asparaginase, gaps early in therapy following intensification, and overall lack of compliance in maintenance) are being explored in the latest protocol ALL '97. Cranial irradiation had been successfully replaced by a long course of intrathecal methotrexate injections for the majority of patients. Age (Ͻ1 year Ͼ10 years) sex (male) and white count Ͼ50 × 10 9 /l plus slow initial bone marrow clearance were consistently the most important independent prognostic indicators during this time period. Rome/NCI criteria accurately predict standard and highrisk groups for B cell lineage, but not consistently for T cell disease. This international collaborative venture might help us to define those truly at highest risk, and how we can optimise therapy for specific subgroups including T-ALL and those with unfavourable cytogenetics. Leukemia (2000) 14, 2307-2320.
Introduction
Since 1970, the UK Medical Research Council Working Party on Childhood Leukaemia has conducted a series of therapeutic trials for acute lymphoblastic leukaemia, with a progressive increase in the percentage of cases entered. In the time period 1980-1997, 80-90% of all patients presenting with acute lymphoblastic leukaemia in the ages 0-15 were entered into three consecutive trials described in this paper. Reasons for non-entry included: individual centres piloting succeeding trials, an alternative national trial existing for specific sub-types of leukaemia, (for example infant leukaemia post-1992, and B cell ALL from 1985), and following individual family or physican preference. The total population-based high accrual rate has facilitated health service planning and made outcome results generalisable to the whole population. The broad principles of therapy had been established by 1972 and in a series of trials (UKALL II-VII) various aspects of the basic protocol were tested. In general the results proved somewhat disappointing with less than 50% of the 1470 patients entered into the Medical Research Council Studies between 1972 and 1979 remaining in first remission at 4 years. 1 UKALL VII (1979) (1980) gave somewhat better results for a small group of standard-risk patients, 2 but not as impressive as results emerging at that time from the Berlin/Frankfurt/Munster group (BFM), 3 and certain American trials. 4 This led to the start of collaboration with the United States Children's Cancer Study Group who gave permission for the UK Working Party to utilise protocol CCSG162 (specifically arm 1A) as our standard therapeutic protocol. This was designated MRC trial UKALL VIII. This study and trial reported the single greatest improvement in event-free survival seen in the UK up to that time, 1 emphasising the value of international sharing of information and collaboration. Publication of longer-term results of closed trials over a predetermined era in a consistent way using agreed risk groupings (eg according to Rome/NCI criteria) further assists such international collaboration and comparison of outcome measures provided all the series being presented are truly population based, and not highly selected.
Materials and methods
From 1980 to 1997, 4568 consecutive patients aged 15 years or younger with de novo acute lymphoblastic leukaemia were enrolled into three successive treatment protocols (UKALL VIII, X and XI; UKALL IX being for adult patients only). Fortyone patients were not eligible on the basis of wrong diagnosis, or sub-type of leukaemia, for example mature B cell, for which an alternative UK strategy was available. Consequently there were 4527 eligible patients actually treated in the three trials (UKALL VIII, 825; UKALL X, 1612; UKALL XI, 2090). Diagnosis in all three trials was based on standard local hospital morphological review by an expert haematologist, supported by a centralised review panel who also reviewed early response and marrows from non-remitting patients. 5 Early response was defined by percentage of marrow blasts at day 14 in UKALLVIII and X and at day 8 in UKALLXI. The panel members changed over the time period, but with an in-built overlap and succession planning to ensure diagnostic consistency throughout the trial periods. Immunophenotyping has been progressively perfected over this long time period (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) , but for all of the MRC trials there has been a recommended standard panel of immunophenotyping tests using monoclonal antibodies to define lineage-specific antigens. The panel of tests recommended included: anti-CD2, -CD7, -CD10, -CD13, -CD19, -CD33, -CD34, HLA-DR, terminal deoxynucleotidyl transferase (tdt) and cytoplasmic immunoglobulin staining (cyt). Children in the trials have been basi-cally classified for outcome analysis into six main immunophenotypic groups (using a cut-off point for positivity at 20% or above of positively reacting cells for CD10, CD13, CD33, HLA-DR and cytoplasmic immunoglobulin and 30% for other markers):
1 Early preB or null, based on CD10 negativity, CD19 positivity, tdt positivity, and negativity for T cell markers. 2 Common ALL: CD10 positivity, CD19 positivity, tdt positivity and T cell marker negativity. 3 Pre B, the same as common, but with also cytoplasmic immunoglobulin positivity. 4 T cell disease was classified as CD2 and/or CD7 positive, but CD19 and HLA-DR negative. 5 An unusual category has always been identified by patients who expressed so-called myeloid antigens, either CD13 or CD33. 6 Finally other patients whose antibody profile did not fit into any of the above five categories.
It has been consistently possible to divide all ALL cases into either of B lineage or T cell lineage, 6 and it is these broad categories which have been uniformly used for consistency in this series of papers.
Only mature B cell ALL patients (surface immunoglobulin positive) have been excluded from any of the trials on the basis of immunophenotype. Similarly the rate of successful cytogenetic analysis requested and performed has changed over the 17-year period with an increasing recognition of its importance, the use of chromosomal banding techniques and more recently the introduction of fluorescence in situ hybridisation (FISH) to identify specific translocations. Cytogenetic analysis was performed successfully on 281 (34%) in UKALL VIII, 7 830 (51%) in UKALL X 8 and 1658 (79%) in UKALL XI. 9 The three Medical Research Council protocols were designed by a working group of co-ordinators, then approved and modified by the full childhood working party and then subjected to independent peer review, firstly by a leukaemia steering committee and then by a separate data monitoring and ethical committee. Approval for individual patient entry was subject to local research ethical committee review for each hospital centre participating.
Treatment
Details of the three studies have been described elsewhere ( Figure 1) . 1, 7, [9] [10] [11] UKALL VIII (September 1980-December 1984) 1, 7, 10 This study aimed to test whether we could reproduce directly the more favourable results being reported by CCSG. 4 All children with ALL aged 0-14 years inclusive were eligible. Eight hundred and thirty-two patients were entered but four children had surface immunoglobin-positive B cell ALL for which the protocol was not designed, and three patients were found not to have ALL, with the consequence that 825 are analysable. In the first year (designated UKALL VIIIS) running from September 1980 to October 1981, all patients irrespective of their initial prognostic features received a three-drug induction regimen of weekly vincristine (1.5 mg/m 2 /dose) × 5, 28 days of oral prednisolone (40 mg/m 2 per day) and nine intramuscular injections of asparaginase (6000 IU/m 2 /dose) given three times per week for 3 weeks. The asparaginase used was initially Escherichia coli asparaginase (Merck, Sharp, Dohm) as per the CCG162 protocol, 4 but subsequently Erwinia asparaginase was used. 12 After the first year a single randomised variable was introduced (November 1981 to December 1984) to receive two doses of daunorubicin (daunomycin) 45 mg/m 2 per dose intravenously on days 1 and 2 of induction (arm B) or not (arm A which was consequently identical to UKALL VIIIS). No gaps or reduction in induction therapy were permitted. Central nervous system-directed therapy consisted of intrathecal methotrexate (dosage based on age 13 ) at days 0, 15 and 28 and then weekly × 3 during cranial irradiation (18 Gy in 10 fractions) given immediately after achievement of remission. 6-Mercaptopurine was given at a dose of 75 mg/m 2 per day orally throughout CNS irradiation therapy and continued along with oral weekly methotrexate 20 mg/m 2 in continuing therapy with monthly pulses of intravenous vincristine (1.5 mg/m 2 ) and 5 days of oral prednisolone (40 mg/m 2 /day). Between September 1980 and December 1980, the duration of therapy was for 2 years from the time of achievement of remission, but subsequently from January 1981 to the close of the trial in December 1984 there was a randomisation for those still in remission at 2 years, between 2 or 3 years of continuing therapy (the duration dated from achievement of clinical remission). All patients were treated on this protocol irrespective of initial presenting features. Those not in remission at day 28 were given 2 further weeks of vincristine and prednisolone, but thereafter considered off-protocol if not in complete remission. Twenty infants under the age of 1 year were enrolled in UKALL VIII.
UKALLX (1985-1990)

11
This trial was open to all children aged 0-14 years except for those with surface membrane immunoglobin positive B cell ALL. Sixteen hundred and twelve eligible patients were enrolled and a further 23 initially entered had sub-types of leukaemia ineligible for this trial or had a wrong diagnosis also rendering them ineligible for the trial. Induction therapy was identical to UKALL VIIIB (vincristine, prednisolone, daunorubicin and Erwinia asparaginase + intrathecal methotrexate on days 0, 15 and 28). Bone marrow response was again centrally assessed at day 14. This trial was designed to test the benefit of post-remission intensification. On achievement of remission at day 28, patients were randomised to receive no intensification block (arm A consequently identical to UKALL VIIIB) an early block at week 5 (arm B) or a late block at week 20 (arm C), or both an early and late block (arm D). The philosophy of the group since 1980 has always been to carry forward the best arm of each trial as the standard arm of the next. The composition of the two intensification blocks was identical and consisted of a 5-day course of cytarabine /day with a gradual wean over 3/4 days after the early block). Intrathecal methotrexate was given on day 1 of each block. Following each of these modules, moderate to severe pancytopenia was observed at 7-10 days with recovery adequate to allow recommencement of therapy within 3-4 weeks.
14 The CNS-directed therapy phase was the same as in UKALLVIII (18 Gy cranial irradiation plus three intrathecal injections of methotrexate). During irradiation oral 6-mercaptopurine was given daily (75 mg/m 2 /day). Exceptions to the randomisation process included: (1) Patients with CNS disease at diagnosis as defined by more than five cells per l in the CSF, which were recognisable blast cells. These patients were given arm B (early intensification) followed by 24 Gy irradiation to the cranium, and 12 Gy to the spine, and then continuation therapy with no further intensification modules. (2) Children with a white count greater than 100 × 10 9 /l were allocated to arm D, and received cranial irradiation to a dose of 24 Gy unless they had a matched sibling donor when cranial irradiation was replaced by cyclophosphamide and total body irradiation as conditioning for bone marrow transplantation in first remission. 15 These were the only patients in this trial deemed to be suitable for bone marrow transplantation in first remission. (3) From January 1985 until April 1988 females aged 2-9 years with an initial leukocyte count Ͻ20 × 10 9 /l were allocated to arm A (that is no intensification). This decision was based on initial anxiety about the toxicity of the intensification modules. From April 1988 onwards, such patients were also entered into the randomised trial. UKALLXI (October 1990 -March 1997 9, 16 This trial recruited all ALL patients aged 1-14 years inclusive (up to their 15th birthday), except those with mature B cell ALL and infants under 1 year. 2090 eligible patients were treated on the protocol with 11 other patients excluded because of wrong diagnosis. Induction therapy was identical to UKALLX (and consequently arm B of UKALLVIII) until May 1992, when the two doses of daunorubicin were dropped from induction to reduce total anthracycline exposure to 180 Leukemia mg/m 2 , in view of worries about late cardiotoxicity then being reported. 17 Initially all patients except those with CNS disease at diagnosis (who were treated with modified UKALLXB and from 1994 on a modified UKALLXD regimen) were randomised between regimens UKALL XC and UKALL XD. From May 1991 as a result of interim analysis showing benefit for two intensification modules all new patients were allocated to the UKALLXD arm (two intensification modules at weeks 5 and 20) , and from May 1992 all new patients were subsequently randomised between two and three intensification modules (this is when the induction anthracycline was also omitted). The third intensification block differed from the previously used pulses and was given between weeks 35 and 42. It consisted of an 8-week schedule (dexamethasone 10 mg/m 2 orally × 10 days, with a tapered reduction over 4 days, vincristine 1.5 mg/m 2 intravenously on days 1, 7, 14 and 21, l-asparaginase (Erwinia) 6000 IU/m 2 subcutaneously or intramuscularly three times per week × 9 doses, intrathecal methotrexate on days 1 and 28, intravenous cyclophosphamide 600 mg/m 2 Throughout the trial, the principal randomised question related to the best method of CNS-directed therapy, to test if cranial irradiation could be safely omitted for standard risk patients, and whether high-dose intravenous methotrexate (6-8 g/m 2 ) could have some systemic benefit as well as controlling minimal CNS disease. Consequently for patients with an initial peripheral blood white cell count Ͻ50 × 10 9 /l randomisation was between a long course of intrathecal methotrexate alone (four doses in weeks 9-12 and 3 monthly throughout 2 years of continuing therapy, to a total of 16 intrathecal doses) or high-dose systemic methotrexate in a dose )) in weeks 6, 8 and 10, with four doses of intrathecal methotrex-ate as well as 3 monthly throughout continuing therapy, also to a total of 16 doses. For those with an initial white count Ͼ50 × 10 9 /l with a known increased risk of CNS disease, randomisation was between high-dose systemic methotrexate (6-8 g/m 2 ) with a long course of intrathecal methotrexate and cranial irradiation to a dose of 24 Gy (in 15 fractions of 1.6 Gy per fraction) with a short course of seven doses only of intrathecal methotrexate. All intrathecal doses were calculated on the basis of age, 13 and the high-dose methotrexate administered as per Moe et al. 18 In parallel with the CNS-directed therapy trial, a psychometric study has been conducted testing the long-term learning and neuropsychological effects of the different CNS treatments. One patient was aged under 1 year at diagnosis, but was entered in the study as he was a year old at registration, but this trial specifically excluded infants under 1 year, for whom different UK trials ran between 1990 and 1997.
Statistical analysis
Overall survival (OS) is defined as the time from diagnosis until death whilst event-free survival (EFS) is defined as the time from diagnosis until either relapse (haematological, CNS or other site or a combination thereof) or death due to any cause, whether or not the patient went into remission. Time to an isolated CNS relapse was defined as the time from diagnosis to a CNS relapse without relapse at any other site, but excluding patients who did not go into remission. Time to any CNS relapse includes both time to any isolated CNS relapse and to a CNS relapse in conjunction with relapse at any other site, occurring within 30 days of the CNS relapse. Actuarial event-free survival, overall survival and time to isolated/any CNS relapse curves were calculated by the method of Kaplan and Meier with the data censored at 31 October 1999. Results were looked at in randomised patients aged 1 year or older at diagnosis divided by cell lineage (Null C or pre-B, T) and Rome/NCI risk (standard risk, age 1-9 years with WBC Ͻ50; high risk, all other patients aged 1 year or more).
Patient follow-up on these trials was carried out by the individual participating physicians in their own centres with an annual trawl of all trial entrants carried out by the Clinical Trial Service Unit each October. Less than 1% of long-term surviving patients are lost to follow-up. Table 1 shows the overall survival and event-free survival in the three reported trials.
Results
Protocol specific treatment outcome UKALLVIII (1980 UKALLVIII ( -1984 7 : Thirty nine of the 825 patients enrolled failed induction (non-remitters + deaths in induction), giving a 95% remission rate. There were 58 (7%) deaths in remission, six from second malignancies and the event-free survival rates (±1 standard error) were 57% (±1.7%) at 5 years, 55% (±1.7%) at 8 years and 54 (±1.7%) at 10 years (see Table  1 ). Median follow-up for survivors is 16.7 years (range 7.2-19.2 years). The cumulative risk of isolated CNS relapse at 5 years was 9% (±1.1%), and of any CNS relapse 14% (±1.3%). For the 20 infants under 1 year of age at diagnosis treated on this protocol EFS was 30% (±10.2) at 10 years.
In those who received induction daunorubicin (arm B) there was twice the rate of induction failures 6% (non-remitters + deaths) compared with arm A (3%) but a reduction in marrow, testicular and combined relapses (30% all relapses arm B, 38% arm A; P = 0.06 odds ratio 0.8 with 95% confidence intervals of 0.6-1.1 7 ), but not of isolated CNS relapse. Deaths in early remission were also higher in those receiving daunorubicin (8% vs 4% of remitters). As a consequence of these conflicting trends there was no significant overall event-free or survival benefit for receipt of daunorubicin. In subsequent trials, a considerable reduction in both induction deaths following more marked myelosuppression with the anthracyclines (principally due to Gram-negative sepsis), and of early remission deaths (10 deaths due to pneumonitis and nine due to measles) was possible, and might well have altered the conclusions reached about the value of induction anthracyclines (see below, Refs 9, 11). For the late randomisation between 2 and 3 years of continuing therapy more relapses were seen after stopping therapy at 2 years (P value for relapse-free survival 0.04), but this was counterbalanced by a 4% death rate in remission with the longer course of therapy, and a higher retrieval rate for those relapsing after 2 years only of treatment. There was consequently no significant survival benefit for those receiving 3 years of continuing therapy in this trial. 7 Patients were not stratified for therapy-based on any initial presenting features. Table 2 shows the treatment results according to presenting features. Although the event-free survival was superior to all previous UKALL protocols and very comparable to results of the CCG 160 series, there was clearly a persistent adverse impact of gender (male sex), age under 1 year, age Ͼ10 years, day 14 blasts and white count above 50 (especially above 100), and apparently of T cell lineage, although in this trial that was not independent of presenting white count. The small number of patients (nine) with CNS disease at diagnosis received weekly intrathecal methotrexate to clear the CSF, and once in systemic remission craniospinal irradiation. They did not have a worsened prognosis. There was inadequate systematically recorded data on cytogenetic results at diagnosis to draw definitive conclusions on the impact of therapy in specific cytogenetically defined subgroups of patients. Day 14 marrows were only routinely assessed for Ͻ5% or Ͻ10% blasts vs those with higher counts. The prognostic power was not improved by taking a cut-off of 10% blasts. Blast cell count at day 14 (Ͻ5%) was highly predictive of outcome (P = 0.0002).
UKALLX (1985-1990)
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:
Forty of the 1612 patients enrolled failed induction (non-remitters + deaths) giving a remission rate of 98%. There were 57 deaths in remission (4%), 14 after a second malignancy. The event-free survival rates for the whole trial were 62% (±1.2) at 5 years and 60% (±1.2) at both 8 years and 10 years. Overall survival was 77% (±1) at 5 years and 71% (±1.1) at 10 years. Median follow-up of survivors is 11.9 years with a range from 2 to 14.8 years (the wide range was due to one patient lost to follow-up at 2 years). The cumulative risk of isolated CNS relapse was 7% (±0.7) at 5, 8 and 10 years, and 12% (±0.9) for any CNS relapse (see Table 1 ). For the 25 infants under 1 year of age at diagnosis event-free survival was 27% (±8.7) at 10 years.
1171 children were randomised to receive intensification at 5 weeks (arm B), 20 weeks (arm C), both (arm D) or neither (arm A). The 5-year disease-free survival is 71% (95% confidence interval 65-76%) for those receiving two blocks, compared with 62% (56-68%) on arm B, 61% (55-67%) on arm at 5 years 14% ± 1.3 12% ± 0.9 15% ± 0.8 at 8 years 14% ± 1.3 12% ± 0.9 15% ± 0.9 at 9 years 14% ± 1.3 12% ± 0.9 Not reached C and 57% (50-63%) on arm A (without any intensification). The benefits of intensification therapy were seen irrespective of all clinical presenting features known to influence outcome such as age, gender and initial leukocyte count. This trial showed a reduction in induction and remission deaths, and a 14% improvement in disease-free survival for those randomised to receive two courses of intensification therapy. All analyses of outcome are based on intention to treat. In 26 patients the allocated additional block of therapy was not given because the parent or doctor perceived the risk of toxicity to be too high. In three cases an additional unallocated block of therapy was given. Careful analysis failed to show any sub-group of children in whom intensification did not appear to be beneficial. This was clearly illustrated by the outcome in females who were initially categorised as low risk.
Comparison of the outcome of the non-randomised girls aged 2-9 years with low initial leukocyte counts (Ͻ20 × 10 9 /l) and those who were randomised was clearly limited because of small numbers. The proportion of relapses among this group of good-risk females who were randomised were six out of 35 in arm A, eight out of 34 in arm B, seven out of 35 in arm C and none out of 32 in arm D, respectively. The principal benefit of the two blocks of treatment appeared to be the prevention of bone marrow relapse. Table 3 shows results according to presenting features: age, leukocyte count and sex remain the most significant prognostic features, followed by response to treatment as measured by day 14 bone marrow blast percentage. The most significant adverse effect was noted for those 31 patients with M3 marrows at day 14 (32% EFS compared with 63% for those with an M1 marrow) There was little difference between those with M1 and M2 marrows at day 14. As in UKALLVIII children with common or pre-B ALL appeared to fare better than those with T cell immunophenotype on univariate analysis, but after stratification for age, gender and leukocyte count immunophenotype was no longer significant. Fifteen patients with Down's syndrome who were treated on this trial and participated in the randomisation had a worse prognosis, largely due to increased treatment-related mortality, with 10 out of the 15 suffering events (2P = 0.02) either deaths in remission or late marrow relapses (following delays in therapy).
11 CNS disease at diagnosis did not confer an overall adverse prognosis on the 29 patients so identified in this trial. 51% of patients had successful cytogenetic analyses and the group of patients with high hyperdiploidy had a more favourable outcome. There was a worse prognosis for those with t(4;11) and for t(9;22). The 16 patients with t(1;19) had a more favourable outcome. 11 However, caution must be expressed due to incompleteness of the data on the whole cohort.
UKALLXI (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) 9 : Fourteen of the 2090 children enrolled failed induction (non-remitters = deaths) giving a remission rate of 99%. Since in this time period over 90% of all children with acute lymphoblastic leukaemia in the United Kingdom were entered into MRC trials virtually all participating physicians tended to treat on this protocol. However there was not a requirement to register patients in this trial until day 28 when the first randomisation occurred. When this very high remission rate became evident, review of all participating centres was carried out to ascertain whether there had been patients who had died prior to formal registration. There were indeed a small number identified, including those patients whose physicians had intended to treat on the protocol but had not registered them because of early death. With inclusion of these the overall remission rate was still 98%. There were 36 deaths in remission (2%), nine in patients who had second malignancies. The event-free survival rate for the whole trial was 63% (±1.1) at 5 years, with an overall survival rate of 85% (±0.8) at 5 and 81% (±1.0) at 8 years, with a median follow-up for survivors of 5.7 years (range 2.5-9.1) at the census point (31 October 1999). The cumulative risk of isolated CNS relapse was 7% (±0.6) at 5 and 8 years and 15% (±0.8) for any CNS relapse (see Table 1 ). Table 4 shows treatment results according to presenting features. The prognostic significance of male sex, age Ͼ10 years and white count Ͼ50 × 10 9 /l persists, as does the presence of t(9;22) and t(4;11). T cell lineage per se is significant in univariate analysis, but not when stratified by white count, age and gender. CNS disease at diagnosis was not of prognostic significance. There was a change in assessment of early response from day 14 to day 8 bone marrow blast percentage in this trial. With the change in protocol after May 1992 when the induction daunorubicin was dropped, it was possible to carry out an analysis on the effect during induction of daunorubicin. In this direction the first 1419 children in the trial were previously reported 19 and 342 received daunorubicin, and up to the time of the report 1077 had not. 44% of the recipients of daunorubicin completely cleared their marrow of blast cells after 8 days, compared with only 13% of the non-recipients ( 2 = 158.2, P value Ͻ0.0001). In addition, 9% of patients who received daunorubicin, but 15% of those who did not, had more than 80% blasts at day 8 ( 2 = 7.7, P value 0.006). In both groups independently the rate of disease clearance correlated with disease-free survival, but there was not a significant difference in overall outcome when comparing the two groups with each other, either in terms of disease-free or relapse-free survival. 19 Those with an M3 marrow at day 8 were significantly more likely to relapse but the discrimination appeared less than seen in UKALLX with a day 14 cut-off. Preliminary analysis of randomised questions in UKALLXI demonstrate a 5-year disease-free survival benefit for those who received the third block of intensification at week 35 (68% with 95% confidence intervals of 64-72% compared with 60% (95% C.I. 56-64) in those who received only two intensification blocks. The difference was principally due to fewer bone marrow relapses amongst patients who received three intensification pulses (relapse rate 24% vs 30%), although in addition the incidence of extramedullary relapses was also non-significantly lower (9% vs 11%). The effect on overall event-free survival remains significant (2P = 0.003) if those events before week 35 (the time at which the third block was actually given) were excluded. Overall survival was not significantly affected by the third block, since there appeared to be a somewhat better salvage in those who had not received a third intensification pulse. This third block of intensification appeared to benefit Leukemia all sub-groups defined by age, white count, immunophenotype or international risk groups. The number of patients with T cell disease was only 35 in the Rome/NCI standard risk group and 82 in the high-risk group, but it is the only group for whom no clear benefit could be shown for the third block. Given the small numbers (with wide confidence intervals) the outcome could still represent either a null effect or indeed a mild benefit for intensification. 9 When the data were combined with those patients in the succeeding trial ALL '97 who were also randomised between three and two blocks, the same outcome was demonstrated. 9 Analysis within groups according to CNS-directed therapy gave very similar results for the effect of a third block in each group, with no significant interaction between the CNSdirected therapy and the effect of a third intensification. 1513 patients were randomised between a long course of intrathecal methotrexate and high-dose methotrexate with intrathecal therapy. On preliminary analysis the isolated CNS relapses were significantly lower with the high-dose methotrexate at 3%, compared with 6% for those who received intrathecal methotrexate (2P = 0.07), and for any CNS relapse the values were 11% and 15% (2P = 0.02). There was no significant difference in terms of deaths in remission by CNS treatment, nor for non-CNS relapses (26% for those receiving intrathecal only and 24% receiving high-dose methotrexate, 2P = 0.9). Disease-free survival by randomised CNS treatment was 66% for high-dose methotrexate and 62% for intrathecal methotrexate (2P = 0.2). So although isolated CNS relapses were reduced with high-dose systemic methotrexate in this trial, no significant benefit in terms of disease-free or overall survival was demonstrated for the addition of this modality of treatment. 16 Further analyses on the method of delivery of the drug and folinic acid are being performed to assess whether these factors have affected outcome. Three hundred and thirteen patients who were randomised to receive either cranial radiotherapy or high-dose methotrexate on the basis of presenting white count Ͼ50 × 10 9 /l. This randomisation was carried through into the next trial ALL '97. Interim analysis has shown no significant difference in terms of isolated CNS relapse, any CNS relapse, non-CNS relapses, disease-free or overall survival between the two arms. Caution should be expressed with regard to this data in view of the small numbers involved and the fact that the randomisation has only just closed (F Hill, personal communication).
Infant ALL
Between 1980 and 1990 infants under 1 year of age at diagnosis were eligible for the trials (VIII and X). Event-free survival figures of 30% between 1980 and 1984 and 27% between 1985 and 1990 (see Tables 2 and 3) were comparable to reports of other trials, but disappointing. A new non-randomised pilot protocol utilising a combination of ALL and AML type therapy was introduced (5-year EFS of 22%). 20 With subsequent modification, this treatment was utilised between 1992 and 1999 for 86 patients with a five-year event-free survival of 35% (Chessells, July 2000, personal communication).
Treatment results by Rome/NCI criteria and lineage in each era
All consecutive patients in each treatment era were enrolled in a single treatment protocol, and eligible for the trial ran- Table 4 Treatment results according to presenting features (UKALLXI 1990 (UKALLXI -1997 Ͻ25% 615 71 ± 1.9 у25% 821 56 ± 1.8 a One patient was aged Ͻ1 year at diagnosis but aged у1 year at registration.
domisations. The percentage of patients from the UK with ALL treated on these trials rose from 80% in UKALLVIII to greater than 90% in UKALLX and XI. Consequently the results and analyses of outcome by prognostic features represent an almost complete picture of a population response to specific therapies in each time period. Table 5 shows the event-free survival by Rome/NCI criteria and lineage for all patients treated in each time period on the relevant trial. Infants under 1 year of age are excluded from these analyses since there was not uniform participation in each of the trials for this group by participating physicians and in the era 1990-1997 there was a separate non-randomised trial. The results for infants are given separately in the text for 1980-1990. Patients with indeterminate lineage are also excluded from this Table. The proportion of patients defined as standard risk by the NCI criteria in these trials is 65-70% and high risk 30-35%. The 5-year and 8-year event-free survival has progressively improved in each consecutive trial for standard risk B cell lineage ALL. The NCI criteria have clearly delineated those with B cell lineage and a more adverse outcome, but for those high-risk patients survival has not significantly improved with time (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) . For T cell ALL only in UKALLX did the criteria clearly define a less favourable prognostic group. There is not a consistent improvement with time for the small numbers of standard risk T cell patients, whereas there does appear to be a more favourable trend for high risk T cell patients. Overall in UKALLX and XI high-risk T cell patients do not appear to fare significantly worse thanhigh risk-B lineage patients, whilst standard-risk T cell patients do appear to experience more events than those with B-lineage ALL and standard risk features. Table 6 shows the results using Rome/NCI criteria (and lineage) by treatment arm for UKALLVIII (study 1980-1981 and trial 1981-1984) . The NCI criteria defined consistent prognostic significance for B-lineage ALL, although this was more clear cut in the non-randomised study and in the B arm of the trial (patients who received daunorubicin) than in arm A. This variation and the inconsistent pattern for T-ALL may result from the relatively small numbers involved. Data are also included for those randomised between 2 and 3 years of Standard risk is defined as those with WBC Ͻ50 × 10 9 /l and aged 1-9 years at diagnosis High risk, all other patients.
Table 6
Treatment results by ROME/NCI criteria and lineage [1980] [1981] [1982] [1983] [1984] therapy for those reaching the 2-year time-point. The NCI criteria no longer clearly define an adverse prognostic group in this trial after 2 years of treatment. Table 7 shows the results for the era 1985-1990 for those randomised within UKALLX. These figures exclude those with indeterminate lineage ALL, the 29 patients with CNS disease at diagnosis (seven of whom also had an initial WBC у100) who were allocated arm B plus craniospinal irradiation, the 205 with a white count Ͼ100 × 10 9 /l who were allocated (not randomised) to arm D or to receive an allogeneic bone marrow transplant if they had a compatible sibling match, 15 and before April 1988 females aged 2-9 years (n = 207) with a white cell count Ͻ20 × 10 9 /l (who were not initially randomised because of the perceived toxicity of intensification). The data demonstrate the benefit of two intensification modules which is most significant in standard-risk patients with B-lineage ALL. The numbers are too small to determine true benefit of intensification for standard risk T-lineage patients. For highLeukemia risk patients (defined by the NCI criteria) of any lineage the benefits of intensification are less consistently demonstrated. Table 8 shows the treatment results by NCI criteria and lineage for UKALLXI 1990-1997. For B-lineage leukaemia during the first year of the trial when patients were randomised between arm C of UKALLX and arm D, the NCI criteria did not consistently define prognostic significance, but once all patients were receiving either two or three intensification modules there was a clear definition between standard-and high-risk patients, with a greater benefit accruing to patients with standard risk for the use of three intensification modules. With T-lineage there was again a very inconsistent pattern and although the numbers are small, there is not an overwhelming trend for benefit for a third intensification block. Similarly for CNS-directed therapy, intrathecal methotrexate is not associated with a favourable outcome in the four patients with T cell ALL in the high risk group, whilst conversely high-dose methotrexate appeared to be associated with a poorer prognosis in Table 7 Treatment results by NCI risk grouping and lineage [1985] [1986] [1987] [1988] [1989] [1990] (UKALL X) the 21 patients with standard risk. These variations are almost certainly merely a reflection of the small numbers involved.
Overall conclusions on prognostic factors
Throughout the time period 1980-1997, features consistently associated with a more favourable prognosis include female gender, aged between 1 and 9 years, white count under 50 × 10 9 /l and those who achieved M1 status (5% marrow blasts) at either day 8 or day 14. M3 status at day 14 was predictive of a poor outcome and more disseminating than M3 at day 8. Figure 2 shows overall survival by trial which was 65% in UKALLVIII (1980) (1981) (1982) (1983) (1984) , and 71% in UKALLX (1985) (1986) (1987) (1988) (1989) (1990) ) at 10 years, and in UKALLXI 80% at 9 years (81% at 8 years, Table 1 ). The comparable event-free survival figures ( Figure  3 ) are 54% UKALLVIII and 60% in UKALLX (10 years) and 60% in UKALL XI (8 and 9 years). Figure 4 shows cumulative isolated CNS relapse risk 9% in UKALLVIII, and 7% in UKALLX (at 10 years) and 7% in UKALLXI at 8 years. Figure  5 shows 8-year rates for any CNS relapse: 14%, 12% and 5%, respectively in the three trials.
Survival curves
Figure 2
Overall survival for three UKALL trials: VIII (1980 VIII ( -1984 , X (1985-1990) , XI (1990 XI ( -1997 .
Figure 3
Event-free survival for three consecutive ALL trials (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) .
Discussion
Although the results of the trials included in this paper have been published before 7, 9, 11 at an earlier stage of follow-up, as has the rationale behind their development, 21 the opportunity to present longer-term follow-up back to back with many other international groups provides an ideal opportunity to compare the impact of therapeutic interventions in different sub-groups. The key to the success of such a project lies in international collaboration, and the necessity of reporting data in a consistent and uniform way according to pre-determined criteria. That this has been achieved is a triumph in itself. Such collaboration is already leading to a worldwide co-ordinated approach to the problem of the rarer forms of childhood ALL (for example those with t(9;22), t(4;11)), near haploidy etc) which cannot be tackled on a national basis. Even in these three UK trials involving 4527 patients, there were only 402 T cell patients (82 with standard risk) making interpretations of effects of therapy at best speculative.
Leukemia
The advance which the UK made in the early 1980s owed a lot to close collaboration with the US Children's Cancer Study Group, and adoption of one of their standard-risk protocols for all of our patients. 4, 7 The results justified the action with an 11% overall improvement in disease-free survival compared with the previous standard treatment in UKALL trials II-VII, 1 and as least as good a result for standard-risk patients as reported by CCSG. 4 The next trial, UKALLX, showed a continuing improvement in disease control, especially for those receiving two intensification modules, but even those treated on arm A with no intensification had better overall survival than those treated on arm B of UKALLVIII with identical treatment, largely due to a significant decrease in both induction and remission deaths. In UKALLXI disease control, most especially prevention of bone marrow relapses, was greater in those who received three intensification modules for B lineage and possibly T lineage patients compared with those who only received two but this has not translated into a long-term overall survival benefit. It appears that those relapsing after two 
Figure 5
Cumulative risk of developing any CNS relapse by UKALL trial (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) . At 8 years, risks are 14% (±1.3), 12% (±0.9) and 15% (±0.9), respectively, in trial VIII, X and XI. intensification modules were more salvageable than those relapsing after three pulses. The recently reported results of the UKALL R1 study demonstrate a greater success in retrieving patients within the UK, at least those who relapsed more than 6 months off treatment (5-year event-free survival at 57%), with chemotherapy alone, compared with other published series. 22 This may explain why overall survival, but not eventfree survival in the UK series is comparable to the CCSG data in the era 1990-1997. However, event-free survival in both standard but more noticeably high-risk patients has lagged behind. Although patients may be salvaged with retreatment, it is at the price of greater toxicity. It is this failure to advance in terms of disease control which has led to an adoption of double delayed intensification modules in the current ALL protocol (and the treatment strategy of CCG 1951), as well as to intensify therapy for patients with slow early response. The adverse impact of a marrow with 25% or more blasts at day 14 was clearly demonstrated in UKALLX and at day 8 in XI, warranting attempts to intensify treatment for patients so defined.
Cumulative risk of isolated CNS relapse has not increased with the replacement of cranial irradiation by long course intrathecal methotrexate or by high-dose systemic methotrexate, plus intrathecal therapy. Isolated CNS relapses were reduced with high-dose methotrexate and intrathecal therapy in UKALLXI for those with an initial WBC Ͻ50 but no significant benefit in terms of disease-free or overall survival was seen compared with intrathecal therapy only. The cumulative risk of both isolated and combined relapses involving the CNS are higher in the UK than in some reported series, and may reflect on the type of intensification utilised and/or the dose and type of steroid used. The use of dexamethasone is being compared in a randomised fashion in the current UKALL '97 trial.
Consistent predictors of poorer outcome throughout the time period 1980-1997 have been male sex, age under 1 year, white count Ͼ50 × 10 9 /l and those with t(9;22) and t(4;11) plus slow early response as measured by bone marrow blast percentage at either day 14 or day 8. Although the NCI criteria have by and large defined more or less favourable groups with B-lineage leukaemia it has not always been independent of therapy. For example, in arm A of UKALLVIII, where there was no induction anthracycline or intensification involved, event-free survival was comparable in standard and high risk as it was in arm A of UKALLX (no intensification) and for the small number of patients treated in UKALLXI on arm C (that is a late block of intensification only). These variations may be a reflection of small numbers, but it does emphasise that prognostic criteria are clearly never fully independent of the therapy utilised. For T cell disease, the numbers treated are small, and many of the variations may merely be a reflection of that, but it is of interest to note that arm D of UKALLX gave the best overall event-free survival in both standard-risk and high-risk patients, and that the high-risk T cell patients, albeit only 12 patients, actually fared better than high risk B-lineage patients. For T cell disease there was a failure generally for Rome/NCI criteria to discriminate between standard-and high-risk patients. However, for those patients in UKALLXI with T cell disease, not only did the criteria not discriminate between standard-and high-risk for outcome, but the survival in the small series of patients was very comparable whether they had a third block of intensification or not.
The reasons for the failure in the UKALL trials to significantly further improve event-free survival, particularly for standard-risk patients in more recent years (1990-1997) is far from clear. A number of basic aspects has been considered including the use during induction of 40 mg/m 2 /day of prednisolone rather than 60 mg/m 2 ; the lack of use of dexamethasone; the dropping of daunorubicin from induction, the potentially sub-optimal route of administration (s.c.), dosage, and scheduling of asparaginase, the presence of a gap to allow recovery of normal marrow following early intensification between weeks 5 and 8 (and again between weeks 20 and 23), as a result of the form of intensification used in UKALLX and XI, and a possible lack of intensive and strict compliance with delivery of continuation therapy to the patient. Chessells et al 23 demonstrated that children in UKALLX with one or more episodes of neutropenia with a count of Ͻ0.5 × 10 9 /l had an improved prognosis compared with those who never became neutropenic. Whether neutropenia or lymphopenia induced by continuation therapy is the best guide of efficacy remains unclear, but it is certain that to be successful certainly for most childhood ALL, therapy must be of 2-3 years duration and induce significant immunosuppression. The questions of type of steroid and thiopurine during continuing therapy are key questions being addressed in the current ALL '97 protocol, as is the use of more sustained protracted intensification modules comparable to those used by the Children's Cancer Study Group and BFM. 3 It is hoped that use of sustained intensification with minimal gaps (for recovery time), and of continuation therapy prolonged to 3 years for boys will prove more effective for standard-risk patients, with high-risk (NCI criteria) patients having more intensive induction and intensification. For all there should be a built in assessment of initial response (as assessed by blood blast count or marrow blasts), enabling slow responders to be selected out for augmented intensification and intensified maintenance therapy. The publication of this Leukemia series of papers may afford an opportunity to address the questions of whether specific therapeutic approaches do benefit subtypes of childhood ALL. The UK Trials VIII-XI have shown benefit from the receipt of intensification modules used in all subgroups, but a greater percentage of patients (30-40%) would appear to be of higher risk of relapse than hitherto we have defined in UK studies. Schrappe et al 24 have clearly defined the adverse effect of slow peripheral blood and marrow cytoreduction. Nachman et al 25 have demonstrated the value of an augmented approach for those with high risk and/or a slow initial response, and this strategy has been adopted in our current trial. What we do require is a consensus as to the most efficacious and cost-effective way of defining slow response and/or persistent minimal disease, and when we should adjust therapy in response to such disease persistence.
